A pair of wearable stickers may transform diagnostic sweat testing for cystic fibrosis (CF), a genetic disorder that causes problems with digestion and breathing.
A joint research team led by professors Sungsu Park of Sungkyunkwan University and Sun-Ha Paek of Seoul National University College of Medicine has demonstrated for the first time that the sequence in which immune cells interact with cancer cells can critically influence the therapeutic response in glioblastoma.
Many people who survive a heart attack will later develop heart failure due to the scarring that occurs as the heart heals.
A previously unknown microprotein hidden within the human mitochondrial genome may help explain certain forms of type 2 diabetes and could point toward a new precision medicine approach to treating it, according to a new USC study.
A scientific collaboration between the University of Bath (UK) and the UMass Chan Medical School (U.S.) has determined how a specific type of white blood cell—neutrophils—moves through the body.
PITTSBURGH, July 29, 2026 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for CHC. The Gwyn Lo dosage is norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day.
WEST ORANGE, N.J., July 29, 2026 /PRNewswire/ — Researchers from RWJBarnabas Health and Rutgers Robert Wood Johnson Medical School found that an artificial intelligence (AI)-enabled early warning system helped identify hospitalized patients at risk of rapid clinical decline sooner, contributing to fewer deaths among high-risk patients.
A gene-editing tool designed to precisely rewrite the gene that causes Huntington’s disease reduced toxic protein fragments and symptoms associated with the disease in mice, researchers at the University of Illinois Urbana-Champaign report.
A single IV injection of a microRNA-based biologic developed by Guangping Gao, Ph.D., Robert H. Brown Jr., DPhil, MD, Jun Xie, Ph.D., and Zuoshang Xu, MD, Ph.D., suppressed production of the mutant SOD1 protein that causes amyotrophic lateral sclerosis (ALS), delayed disease onset by 60 days and extended lifespan by 100 days—more than tripling the average survival time—in mouse models of the disease.
Wearable health monitors have grown increasingly capable, but most are still limited by the fact that tracking different types of body signals requires separate sensors, each with its own circuitry and patch of skin. That leads to bulkier devices, higher power consumption and greater discomfort for anyone who needs round-the-clock monitoring.